Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 20/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 17/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260821 | 0.92 | ADORA3 (0.68) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL260728 | 0.90 | ADORA3 (0.64) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL12935984 | 0.88 | ADORA3 (0.78) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL12935988 | 0.88 | ADORA3 (0.76) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL260662 | 0.85 | ADORA3 (0.49) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL12935990 | 0.79 | ADORA3 (0.74) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL12935985 | 0.79 | ADORA2A (0.77) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL5461254 | 0.78 | ADORA2A (0.80) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL280495 | 0.78 | ADORA2A (0.63) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL260619 | 0.77 | ADORA3 (0.54) | ADORA3ADORA1ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | PNP, NUDT1, HPRT1 | ADORA3 26/4885ADORA1 22/4885ADORA2B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.